GastroGard the first imported equine drug in China GastroGard the first imported equine drug in China GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.
Trailr2-cdh17-antibody-phase1-trial Trailr2-cdh17-antibody-phase1-trial Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Full data chronic kidney disease trial efficacy Full data chronic kidney disease trial efficacy Positive full data results announced from the EMPA-KIDNEY Phase III trial in adults with chronic kidney disease
Odile Bain Memorial Prize 2021 Odile Bain Memorial Prize 2021 Brilliant early-career scientists in parasitology recognized
Partnering-with-google-in-quantum-computing Partnering-with-google-in-quantum-computing New cooperation with Google explores the potentials of quantum computing for pharma R&D.
Partnership for first-in-class cancer and CRM treatments Partnership for first-in-class cancer and CRM treatments Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
Our Venture Fund on the search for groundbreaking trends Our Venture Fund on the search for groundbreaking trends The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
Positive-CHMP-opinion-for-dabigatran-in-children Positive-CHMP-opinion-for-dabigatran-in-children Positive CHMP opinion received for use of dabigatran for the treatment and prevention of venous thromboembolic events in children
New Partnership to Develop Gene Therapy for Cystic Fibrosis New Partnership to Develop Gene Therapy for Cystic Fibrosis Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
EMPA-KIDNEY trial early stop due to positive efficacy EMPA-KIDNEY trial early stop due to positive efficacy EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy
New Therapeutic Antibody Discovery Collaboration New Therapeutic Antibody Discovery Collaboration Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets
Research-collaboration-Gubra-obesity-treatment Research-collaboration-Gubra-obesity-treatment Boehringer Ingelheim and Gubra enter collaboration to identify and validate targets and innovative peptides for the treatment of obesity.
collaboration-LIBD collaboration-LIBD Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
InPedILD_trial_enrollment InPedILD_trial_enrollment First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Perceived burden of COPD is higher for younger patients Perceived burden of COPD is higher for younger patients New global survey reveals perceived burden of disease is greater in younger people living with COPD
FOYA_Shanghai FOYA_Shanghai Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
FDA-Fast-Track-chronic-kidney-disease FDA-Fast-Track-chronic-kidney-disease FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition
CARMELINA-elderly-analysis CARMELINA-elderly-analysis CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
Geographic Atrophy treatment to move to Phase II Geographic Atrophy treatment to move to Phase II Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results
The impact of carbon reduction projects The impact of carbon reduction projects Boehringer Ingelheim voluntarily contributes to carbon reduction projects that benefit sustainable development.
Clinical-phase2-trials-NASH-and-obesity Clinical-phase2-trials-NASH-and-obesity Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
GioTag Final Data GioTag Final Data Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
discontinuation-bi-1467335-diabetic-retinopathy discontinuation-bi-1467335-diabetic-retinopathy The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
new_analysis_nintedanib_SSc_ILD new_analysis_nintedanib_SSc_ILD Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
Phase II results cognitive impairment schizophrenia Phase II results cognitive impairment schizophrenia Presented at ECNP Congress, Phase II trial results demonstrated improvement in cognition with BI 425809 in schizophrenia patients